Fecal Microbiota Transplantation for Health Improvement (TFM3)
NCT ID: NCT04011943
Last Updated: 2019-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2018-05-21
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Faecal Microbiota Transplantation (FMT) in Patients With IBSmechanism(s) of Action
NCT04236843
Fecal Microbiota Transplantation for Irritable Bowel Syndrome
NCT03613545
FMT in the Treatment of IBS
NCT03561519
Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT05740319
Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome With Constipation
NCT05803993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To select donors of fecal samples for carrying out the procedure of fecal transplantation of microbiota to patients with various nosological forms.
2. To select healthy volunteers for autologous and heterologous transfusion of feces and a group of placebo-control.
3. Create a bank of fecal samples of healthy donors;
4. Conduct a procedure for fecal microbiota transplantation for a sample of patients and healthy volunteers;
5. Analyze the efficacy of therapy with TFM on the sample of patients;
6. Analyze the effect of autologous, heterologous TFM and placebo on healthy volunteers;
7. Analyze long-term effects in patients within 6 months after the TPM.
The study is expected to include 50 patients, 35 healthy volunteers and healthy feces donors The study is scheduled to begin in May 2018, the supposed completion of the study is December 2020
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
50 participants will form a treatment group.
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with bowel diseases
Treatment by transplantation of fecal microbiota
Fecal Microbiota Transplantation
Fecal Microbiota Transplantation
autologous transplantation of fecal microbiota - healthy
Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)
Fecal Microbiota Transplantation
Fecal Microbiota Transplantation
Both autologous and heterologous transplantation - healthy
Healthy volunteers will receive both autologous and heterologous transplantation (capsules)
Fecal Microbiota Transplantation
Fecal Microbiota Transplantation
placebo capsules - healthy
Healthy volunteers will receive placebo capsules
Fecal Microbiota Transplantation
Fecal Microbiota Transplantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fecal Microbiota Transplantation
Fecal Microbiota Transplantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with:
* antibiotic-associated colitis,
* inflammatory bowel diseases (ulcerative colitis, Crohn's disease),
* diseases caused by C. difficile infection,
* a syndrome of impaired intestinal absorption,
* irritable bowel syndrome,
* celiac disease (severe form),
* metabolic syndrome, including diabetes mellitus type II,
* Atopic dermatitis with damage to the mucous membrane of the colon,
* hepatitis of various etiologies,
* cirrhosis of the liver of various etiologies
* pancreatitis of various etiologies,
* Absence of contraindications to gastroscopy
* informed consent of the patient for the transplant procedure
Exclusion Criteria
* Patients with a proven allergy to foods not excluded from the donor's diet
* absence of the patient for one or more intermediate stages of the examination.
* informed refusal to continue therapy
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal Research and Clinical Center of Physical-Chemical Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elena Ilina, MD
Role: PRINCIPAL_INVESTIGATOR
FRCC PCM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FRCC PCM
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TFM3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.